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OBJECTIVES: The present study aimed to investigate cardiovascular autonomic modulation and angiotensin II
(Ang II) activity in diabetic mice that were genetically engineered to harbor two or three copies of the
angiotensin-converting enzyme gene.
METHODS: Diabetic and non-diabetic mice harboring 2 or 3 copies of the angiotensin-converting enzyme
gene were used in the present study. Animals were divided into 4 groups: diabetic groups with two and three
copies of the angiotensin-converting enzyme gene (2CD and 3CD) and the respective age-matched non-diabetic
groups (2C and 3C). Hemodynamic, cardiovascular, and autonomic parameters as well as renal Ang II expression
were evaluated.
RESULTS: Heart rate was lower in diabetic animals than in non-diabetic animals. Autonomic modulation analysis
indicated that the 3CD group showed increased sympathetic modulation and decreased vagal modulation of
heart rate variability, eliciting increased cardiac sympathovagal balance, compared with all the other groups.
Concurrent diabetes and either angiotensin-converting enzyme polymorphism resulted in a significant increase
in Ang II expression in the renal cortex.
CONCLUSION: Data indicates that a small increase in angiotensin-converting enzyme activity in diabetic animals
leads to greater impairment of autonomic function, as demonstrated by increased sympathetic modulation and
reduced cardiac vagal modulation along with increased renal expression of Ang II.
KEYWORDS: Renin-angiotensin System; Autonomic Nervous System; Renal Angiotensin System; Mice.
’ INTRODUCTION
The clinical relevance of the angiotensin converting enzyme
(ACE) polymorphism was first described in 1990, when Rigat
et al. (1) found a 2-fold increase in serum ACE levels in patients
with the ACE DD genotype compared with ACE II patients.
In concordance with Rigat et al., in recent years, several
studies have demonstrated an association of the DD genotype
and the specific D allele with clinical cardiovascular outcomes,
such as atherosclerosis (2) and increased left ventricular mass
in systemic hypertension (3,4). Moreover, observational data
demonstrated an elevated frequency of the ACE DD genotype
in type 2 diabetes patients (5).
Randomized clinical trials (RCT) have shown the ability of
renin-angiotensin system (RAS) inhibitors to prevent new-
onset diabetes mellitus (DM) and its vascular complications (6).
Meta-analysis data agree with RCT data, showing a reduced
risk of developing DM in patients taking ACE inhibitors or
angiotensin II (Ang II) receptor blockers (ARB). However,
large double-blind RCTs did not confirm the previous hypo-
thesis; one study showed that ramipril was not able to
prevent DM development in patients with impaired fasting
glucose metabolism (7).
Ang II influences several physiological domains in organ
systems, including the autonomic nervous system (ANS).
In fact, Ang II may stimulate the sympathetic system andDOI: 10.6061/clinics/2018/e246
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inhibit parasympathetic outflow. On the other hand, when
Ang II is blocked, reduced sympathetic activity and enhanced
parasympathetic activity are expected (8). Regarding the
ACE polymorphism, animals harboring 3 copies of the ACE
gene, which is accompanied by increased synthesis of Ang II,
demonstrated left ventricular hypertrophy, higher pressure
values, overt proteinuria, and risk of nephropathy, which is
probably associated with autonomic imbalance (9-11). How-
ever, no RCTs or even experimental studies have described
the relationship between autonomic regulation and ACE gene
polymorphism in DM. This relationship, however, deserves
attention, as renal RAS is clearly activated in DM (12).
Therefore, this study aimed to investigate hemodynamic
and autonomic control as well as the renal expression level of
Ang II after induction of diabetes in genetically modified
mice harboring a different number of copies of the ACE gene.
Since RAS activity increases sympathetic afferent signals in
response to renal ischemia, which in turn causes increased
central sympathetic outflow (13), we hypothesized that in
the presence of increased Ang II in the kidney, autonomic
dysfunction would be proportionally augmented based on
the number of ACE gene copies.
’ METHODS
Production of transgenic mice
Genetically engineered mice in which the ACE gene was
either inactivated or duplicated at its endogenous locus on
chromosome 11 were developed by using a gene recombina-
tion technique previously described by Krege et al. (14).
Briefly, this technique can be used to insert a sequence of
DNA by recombination in place of the gene to be turned off
(knockout) or insert an extra copy of a gene adjacent to the
existing gene (knock in).
Genotyping
Genetically modified offspring were identified at 21 days
of age by PCR amplification of DNA isolated from ear biopsies
as previously described (14).
After birth, the animals are identified by a chip, an elec-
tronic device inserted subcutaneously in the back during
anesthesia. Each device contains a code with letters and numbers
that can be identified by telemetry through an automatic reader.
The procedure is simple because it requires no sutures, and the
animal fully recovers within minutes.
Experimental groups
Experiments were performed on male mice developed by
Krege et al. (14) (15-20 grams) harboring 2 and 3 copies of the
ACE gene at the central animal house of the Medical School
of University of São Paulo in São Paulo, Brazil. Mice were fed
standard laboratory chow and water ad libitum. The animals
were housed in collective polycarbonate cages in a tempera-
ture-controlled room (22-23o C) and under 54-55% humidity
with a 12-h dark–light cycle (light 07:00-19:00 h). The experi-
mental protocol was approved by the University of Sao Paulo
Ethics Committee (protocol number 1226/06) and carried out
according to the Declaration of Helsinki on Ethical Principles
(as revised in Brazil in 2013).
The animals were randomly assigned into four groups:
mice harboring 2 (2C) (n=6) and 3 (3C) (n=6) copies of the
ACE gene, and STZ-induced diabetic mice with those geno-
types [2CD (n=6) and 3CD (n=6)].
Induction of diabetes
Diabetes was induced in 6-10-week-old male mice by
a single intraperitoneal injection of streptozotocin (STZ,
150 mg/kg, Sigma Chemical Company, St. Louis, MO, USA)
after a 12-hour fasting period. The non-diabetes group received
only a vehicle (10 mM citrate buffer, pH 4.5) injection after a
similar fasting period.
Measurement of blood glucose levels
After a 24-hour fasting period, blood glucose levels were
determined using the ACCU-CHECK Sensors (Roche). Blood
samples were obtained by vessel puncture in the caudal
vein and were used to estimate glucose levels. Animals with
plasma glucose levels higher than 250 dl/ml were included
in the diabetic groups. At the end of the experiments, plasma
glucose was measured, and the mean of initial and final
measurements was presented.
Glucose tolerance test
A glucose tolerance test (GTT) was performed at the end of
the 30-day protocol in all study groups. The animals fasted
for 6 hours and were given a single (i.p.) injection of glucose
(1.5 g/kg). Blood samples were collected from a small cut
made in the tail of each animal at 0 (zero), 5, 15, 30, 60 and
90 min after glucose load, and the area under the curve
(AUC) was calculated. Blood glucose concentrations were
determined using an Accu-Check Advantage Blood Glucose
Monitor (Roche Diagnostic Corporation, Indianapolis, IN).
Cardiovascular measurements
One day after the GTT, at 31 days after diabetes induction,
the animals were anesthetized (ketamine–xylazine 80:40 mg/kg
i.p.), and polyethylene-tipped Tygon cannulas (4 cm of PE-08
connected to 2 cm of PE-50, Clay Adams) filled with hepari-
nized saline were inserted into the carotid artery and jugular
vein for direct measurements of arterial pressure (AP) and
drug administration, respectively. The free ends of the can-
nulas were tunneled subcutaneously and exteriorized at the
top of the skull. After surgery, the animals received an intra-
muscular injection of penicillin G (Benzetacils, Fontoura-Wyeth,
60,000 U). Two days following catheter placement, hemo-
dynamic measurements were taken from animals at baseline
conditions, namely, conscious, freely moving, and in a quiet
environment with controlled temperature but deprived of
food and water. The arterial cannula was connected to a
transducer (Blood Pressure XDCR, Kent Scientific), and AP
signals were recorded for a 20-min period using a micro-
computer equipped with an analog-to-digital converter board
(WINDAQ, 4 kHz, Dataq Instruments). The recorded data
were analyzed on a beat-to-beat basis to quantify changes in
AP and heart rate (HR).
HR and blood pressure variability
Time-domain analysis was carried out by calculating the
mean pulse interval (PI) variance using its respective time
series. For the frequency domain analysis, the whole 30-min
time series of PI and systolic arterial pressure (SAP), which
totaled 256 points with a 50% overlap, was used. Following
linear trend removal, power spectral density was obtained
by fast Fourier transformation. Spectral power for low (LF 0.10-
1.0 Hz) and high (HF 1-5 Hz) frequency bands was chosen
using the methods described by Thireau (15) to calculate
spectral components by the mean of the power spectrum
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density integration within each frequency bandwidth using
a customized routine (MATLAB 6.0, Mathworks).
Assessment of renal angiotensin II
At the end of the study period, the animals were anes-
thetized with an overdose of pentobarbital 120 mg/kg (Critália,
Sao Paulo, Brazil), and nephrectomy was performed. The
right kidney was perfused in situ and prepared for immuno-
histochemical evaluation. Perfusion of the kidney was first
carried out using a saline solution to remove red blood
cells from the vascular lumen followed by a 10% formalin
solution for 3 minutes to preserve the structures. The kidney
was sectioned in the coronal orientation at approximately
4 mm thickness. We measured Ang II expression levels in the
renal cortex. For this quantification, we counted the number
of positively stained cells in 25 consecutive microscopic fields,
and the results were expressed as the mean number of stained
cells per square millimeter. The fragments were kept for
2 hours in a formaldehyde solution plus 10% phosphate
buffer and embedded in paraffin blocks.
For the immunohistochemical analysis, tissues were depar-
affinized and then incubated with the specific primary anti-
body against angiotensin II (Anti-Ang II-rabbit polyclonal
Peninsula, Belmont, CA, USA) and with biotinylated immuno-
globulin goat anti-rabbit antibody (Vector, Burlingame, USA)
diluted 1:1,000 for 45 minutes. Additionally, a complex of
biotin-streptavidin/alkaline phosphatase (Vector, Burlingame,
USA) was added for 30 minutes.
The antigen was stained by fast red dye, and the specificity
of the secondary antibody was established in positive and
negative controls. Images were obtained with a computer-
assisted morphometric system, and the number of positive
cells was expressed as Ang II/mm2.
Statiscal Analysis
Statistical analyses were performed using SPSS software
(Version 17.0 for Windows; SPSS Inc., Chicago, USA). Data
are reported as the mean±SEM. After confirming that all
continuous variables were normally distributed using the
Kolmogorov–Smirnov test, significant differences between
the groups were obtained by two-way ANOVA followed by
the Tukey post-test. All tests were two sided, and statistical
significance was established at po0.05.
’ RESULTS
Glucose levels and hemodynamic parameters
Diabetic animals showed higher plasma glucose levels
as well as lower tolerance to glucose than control animals,
regardless of the number of ACE copies (i.e., 2C and 3C)
(Table 1). Regarding hemodynamic parameters, there were
no differences in blood pressure values (i.e., systolic, diastolic
and mean) between the groups; however, a lower HR was
detected in diabetic animals than in control animals (Table 1).
Autonomic modulation
HR variability, expressed by pulse interval variability
(PIV) in time and frequency domains, is shown in Table 2.
No difference in PI variance was observed between the
groups, thus indicating that diabetes and the number of ACE
gene copies did not change the PIV. However, the 3CD group
showed increased low-frequency bands (%LF) and reduced
high-frequency bands (%HF) of the PIV, which resulted in
increased sympathovagal balance (LF/HF) in the 3CD group
when compared to all experimental groups.
Angiotensin in renal cortex
Figure 1 shows the expression of Ang II in the renal cortex.
Data demonstrated an increase in positive Ang II staining in
the renal tubules of the 3C, 2CD and 3CD groups. Moreover,
Ang II was overexpressed in the 3CD group compared to the
other groups.
Correlation
Correlations were identified between the increase in LFpas
and increase in glucose levels in the control group regard-
less of the number of ACE copies (i.e., 2C and 3C) (r=0.72,
po0.02) (Figure 2A). On the other hand, no correlations were
found between diabetic groups and LFpas (r=0.03, po0.05)
(Figure 2B).
’ DISCUSSION
The present study was the first to demonstrate that STZ-
induced diabetic mice with 3 copies of the ACE gene pre-
sented increased sympathetic modulation and reduced vagal
modulation of the heart. It is important to mention that to the
best of our knowledge, this was the first study to show that
autonomic modulation may be affected by the number of
ACE gene copies in DM.
Conflicting results were found in the literature regarding
the variation of RAS in DM (16). These discrepancies may be
attributed to the different animal models used, the diseases
state and progression, fluctuation levels of the genetically
Table 1 - Metabolic data and hemodynamic evaluation of mice
harboring 2 (2C) and 3 (3C) copies of the ACE gene and STZ-induced
diabetic mice with the same genotype (2CD and 3CD).
Parameters 2C 3C 2CD 3CD
Glycemia (mg/dL) 99±7 97±2 347±34*w 317±62*w
GTT (mg/dL/min) 219±15 278±45* 491±19*w 452±42*w
SAP (mmHg) 122±3.2 125±4 122±4 123±3
DAP (mmHg) 86±4.1 90±5 93±5 94±4
MAP (mmHg) 106±3.1 107±2 102±5 104±5
HR (bpm) 611±14 596±25 467±23*w 513±12*w
Values are expressed as the mean±SEM. DAP: diastolic arterial pressure;
GTT: glucose tolerance test; HR: heart rate; MAP: mean arterial pressure;
and SAP: systolic arterial pressure. *po0.05 vs. 2C; and wpo0.05 vs. 3C.
Table 2 - Autonomic assessment in mice harboring 2 (2C) and
3 (3C) copies of the ACE gene and STZ-induced diabetic mice
with the same genotype (2CD and 3CD).
Variables 2C 3C 2CD 3CD
PIV (ms) 38±8 30±5 20±6 28±5
LF (ms2) 4.6±1 4.8±1 1.8±0.5 16.9±5*#+
HF (ms2) 9.9±1.5 9.2±1.1 3.6±6 12.0±6
%LF 31±4 33±7 37±6 60±7*#
%HF 69±4 67±7 63±6 40±7*#
LF/HF 0.48±0.1 0.56±0.2 0.68±0.2 2.20±0.7*
Values are expressed as the mean±SEM. PIV: pulse interval variability;
LF: absolute values of the low-frequency band of the pulse interval;
HF: absolute values of the high-frequency band of the pulse interval;
%LF: normalized low-frequency band; %HF: normalized high-frequency
band; and LF/HF ratio: ratio of absolute values of low-frequency and high-
frequency bands. *po0.05 vs. all; #po0.05 vs. 3C; and +po0.05 vs. 2CD.
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determined components of RAS and glucose levels reached
during illness (17). ACE gene polymorphisms might also
account for these discrepancies since ACE gene variance is
associated with increased risk of glucose intolerance in the
healthy subjects (18).
Regarding the clinical parameters associated with the diabetic
condition, as expected, diabetic animals showed increased
baseline plasma glucose as well as an increased AUC in
the GTT. Ang II seems to interact with insulin metabolism,
as the 3C group showed higher insulin resistance than
the 2C group. Finally, the ACE genotype did not affect
hyperglycemia.
These findings may be explained by the fact that Ang II
promotes insulin resistance by interfering in the insulin-
stimulated increase in insulin receptor substrate 1-(IRS-1)-
associated PI3K activity (24). In addition, reduced insulin
sensitivity was found in both animals with 3 copies of the
ACE gene and healthy humans with the D allele (18,25).
The ANS and the kidneys crosstalk through renal nerves.
Indeed, Ang II facilitates neurotransmission by enhancing
sympathetic discharge and increasing the arterial pulse,
which increases ganglionic transmission (26). This func-
tion of Ang II is well illustrated by renal denervation, when
the increase in blood pressure is prevented in models of
induced hypertension (27).
Efferent renal sympathetic nerves may modify renal vascu-
lar resistance. In addition, afferent renal nerves are respon-
sible for carrying information from the renal baroreceptor to
the central nervous system (28), thus altering afferent sympa-
thetic nervous discharge. Therefore, afferent sympathetic
nervous discharge may be modulated by an increase in
Ang II expression, as demonstrated in the present study.
Moreover, afferent sympathetic nervous discharge may
impact the central sympathetic tonus and, consequently,
increase sympathetic modulation of the heart in diabetic
mice. Indeed, some studies have shown (26) that increased
Ang II expression in the kidney may damage the central
sympathetic tonus in DM.
On the other hand, Ang II in the kidney may facilitate the
release of noradrenaline from the renal sympathetic nerve
terminal, thus changing the hemodynamic parameters and
contributing to systemic changes in blood pressure control (26).
Figure 1 - Quantification of angiotensin II expression levels in the renal cortex of 2C, 3C, 2CD and 3CD mice by immunohistochemical
staining: (A) Illustrative representation of angiotensin II expression in the experimental groups; (B) bar graph of angiotensin II
expression levels as determined by immunohistochemical staining.
The arrows indicate positive angiotensin II staining. Bar: 400X. *po0.05 vs. the 2C control group, and #po0.05 vs. all groups.
Figure 2 - Linear regression analysis of LF SAP and glucose: (A) in control groups (2C and 3C) and (B) in diabetic groups (2CD and 3CD).
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In the present study, animals were genetically modified
to model the changes and fluctuations in RAS commonly
observed in humans. In fact, this animal model has been
accepted as a useful tool with which to investigate the effect
of vascular and renal ACE on hemodynamic parameters (14).
Regarding hemodynamic parameters, diabetic animals showed
reduced AP levels, and these data are in accordance with
other evidence in the literature (19). However, as previously
described by studies conducted by our group (11) and other
groups (14), no significant difference in AP was observed
among mice with 2 (i.e., ACE2) and 3 (i.e., ACE3) copies of
the ACE gene at the end of the study regardless of the
diabetic condition. A possible explanation of this phenomenon
is the inherently elevated homeostatic capacity presented by
these animals; however, it is important to mention that in
some stressful situations, differences in blood pressure levels
may be observed in this experimental model (20).
Hemodynamic analyses also indicated rest bradycardia
in diabetic groups compared with non-diabetic groups. Evi-
dence in the literature has demonstrated rest bradycardia
and impaired cardiovascular reflexes in experimental dia-
betes animals (21). This finding may be explained by the fact
that the high number of ACE gene copies are associated with
increased Ang II levels, which may trigger additional changes
in intrinsic HR. In this sense, although decreased HR in diabetic
animals has been attributed to changes in the sinoatrial node,
functional alterations in the cholinergic mechanism cannot be
ruled out (22).
Autonomic modulation analysis demonstrated dissimilar
results between diabetic and non-diabetic animals. In non-
diabetic animals, the analysis of PIV in the frequency domain
shows that the normalized LF component of PIV, which
represents the sympathetic modulation to the heart (23), was
not different between the animals with 2 and 3 copies of
the ACE gene, even if different ACE activity was observed
in these animals. However, in 3CD diabetic animals, it was
possible to observe an increased LF band of HR when com-
pared with all other studied groups. These results indicate
that the diabetic state associated with high levels of Ang II
elicited by an elevated number of copies of the ACE gene
may increase cardiac sympathetic modulation.
Last, we explored a possible association between the
peripheral sympathetic component and glucose levels and
found a positive correlation in the control groups (r=0.72,
po0.02) but not in the diabetic groups (r=0.03, po0.05).
Although increased LFpas component was found to be
normal in diabetic groups, in the present study, the diabetic
groups showed reduced LFpas throughout the diabetes time-
course, thus compromising the peripheral nerve and redu-
cing its response, as previously reported in the literature (29).
The amount of Ang II in the renal cortex of diabetic
groups, as evaluated by immunohistochemistry, may be
associated with the relationship between hyperglycemia
and increased RAS activity (30,31). Furthermore, our data
show that the increase in Ang II expression was propor-
tional to the number of copies of the ACE gene, since
the increase in Ang II expression was higher in the 3CD
group than in the 2CD group. These findings suggest that
animals with more ACE gene copies exhibit increased
activation of renal RAS and that this increase is poten-
tiated by diabetes.
Indeed, the increase in the intrarenal formation of Ang II
may change the glomerular hemodynamics (32), as suggested
by Huang et al., (10) whom found several physiopathological
alterations in the renal parameters of diabetic animals with
3 copies of the ACE gene, such as microalbuminuria.
Our data indicate that a small increase in ACE activity in
diabetic animals due to increased ACE gene copies leads to
greater impairment of autonomic function, as demonstrated
by increased sympathetic modulation and reduced cardiac
vagal modulation along with increased renal expression of
Ang II in these groups. Taken together, these results reinforce
the contribution of RAS activation to the development of
cardiovascular and renal changes observed in diabetes.
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